Table 3.
Risk factors for developing de novo donor-specific antibodies after liver transplantation.
| Variable |
Univariate analyses |
Multivariate analyses |
||||
| OR | 95%CI | P value | OR | 95%CI | P value | |
| MELD score > 30 (n = 31) | 1.84 | 0.43-7.10 | 0.33 | - | ||
| Initial liver disease | ||||||
| (1) Alcohol cirrhosis (n = 49) vs (2, 3, 4) | 0.58 | 0.12-2.22 | 0.55 | - | ||
| (2) Viral disease (n = 36) vs (1, 3, 4) | 0.98 | 0.21-3.86 | 1.0 | - | ||
| (3) Autoimmune ILD (n = 13) vs (1, 2, 4) | 1.51 | 0.14-8.46 | 0.64 | - | ||
| (4) Other (n = 18) vs (1, 2, 3) | 2.79 | 0.55-11.83 | 0.64 | - | ||
| Induction therapy, yes (n = 87) | 1.61 | 0.41-7.61 | 0.55 | - | ||
| Polyclonal antibodies (vs other) | 0.59 | 0.70-18.00 | 0.60 | - | ||
| IL2R blockers (vs other) | 1.1 | 0.28-5.28 | 1.0 | - | ||
| Donors’ age > 50 yr (n = 69) | 0.78 | 0.20-3.00 | 0.77 | - | ||
| Recipients’ age > 50 yr (n = 92) | 0.36 | 0.09-1.58 | 0.10 | 0.2 | 0.07-0.85 | 0.3 |
| HCV RNA + at transplantation (n = 21) | 1.41 | 0.23-6.23 | 0.70 | - | ||
| Steroid withdrawal during the FU (n = 19) | 0.39 | 0.01-3.01 | 0.69 | - | ||
| Tacrolimus trough level < 5 ng/mL (n = 34) | 1.59 | 0.38-6.05 | 0.52 | - | ||
| CV-IPV tacrolimus (continuous variable) | 1.92 | -1.28-21.39 | 0.08 | 1.1 | 1.0-1.12 | 0.006 |
| CV-IPV > 35% | 4.66 | 1.22-19.82 | 0.02 | 4.83 | 1.39-16.72 | 0.01 |
| CV-IPV > 40% | 9.10 | 2.28-40.63 | < 0.001 | 9.73 | 2.65-35.76 | 0.001 |
| CV-C0/d-IPV | 3.15 | 5.47-27.31 | 0.005 | 1.0 | 0.97-1.02 | 0.09 |
FU: Follow-up; ILD: Initial liver disease; HCV: Hepatitis C virus; CV-IPV: Coefficient of variability-intra-patient variability; CV-C0/d-IPV: Coefficient of variability corrected for the corresponding daily dose-intra-patient variability.